Report of Foreign Issuer (6-k)
August 14 2020 - 4:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: August 2020
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Financial
Statements
The
unaudited condensed consolidated financial statements for Enlivex Therapeutics Ltd., a company organized under the laws of the
State of Israel (“Enlivex”), as of and for the three and six-month periods ended June 30, 2020 and 2019, and
the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibits 99.1 and Exhibit
99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex’s registration statements on Form
F-3 (File No. 333-232413 and File No. 333-232009), filed with the Securities and
Exchange Commission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Oren Hershkovitz
|
|
Name:
|
Oren Hershkovitz
|
|
Title:
|
Chief Executive Officer
|
Date:
August 14, 2020
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2024 to May 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From May 2023 to May 2024